Damon P. Meyer Email Address

Partner

Highbridge Principal Strategies ("HPS") is a global private investment firm with approximately $24 billion of assets under management. With offices in London, New York, Chicago and Houston, HPS invests across the capital structure in the public and private capital markets. HPS' diversified investment platform includes private equity, mezzanine debt, senior secured leveraged loans, high yield bonds and structured credit products.

Daniel Schubert is a partner in WilmerHale's Securities and Litigation/Controversy Departments. Mr. Schubert concentrates his practice on securities litigation and enforcement matters, as well as commercial litigation, with extensive experience representing investment banks, financial institutions, accounting firms, corporations and individuals in a broad range of complex litigation, regulatory and enforcement matters. Mr. Schubert’s recent white collar and regulatory matters include representing JPMorgan in connection with various law enforcement and regulatory investigations arising out of the so-called 'London Whale' trading losses; representing Morgan Stanley in connection with investigations by the DOJ and SEC into FCPA violations relating to Morgan Stanley’s real estate investing business in China (including the DOJ’s and SEC’s landmark declination in that matter); representing multiple 'Big Four' accounting firms in connection with numerous SEC investigations relating to various auditing and independence matters; representing a large hedge fund in connection with an SEC investigation relating to the 2008 financial crisis; and representing individual executives from financial institutions and other corporations in connection with a variety of regulatory and enforcement proceedings. Mr. Schubert’s litigation matters include representing a large financial institution in connection with a commercial real estate dispute; representing various underwriting groups in connection with multiple putative securities class actions; representing a large, international pharmaceutical company in connection with a contractual dispute and commercial arbitration; representing multiple corporations in connection with merger-related litigation; and representing multiple 'AmLaw 100' law firms in connection with professional liability claims.